March 11 2024

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

February 29 2024

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

February 22 2024

Indivior Announces Q4 / FY 2023 Financial Results

October 4 2023

Indivior Statement on the Availability of OPVEE® (nalmefene) Nasal Spray

January 26 2023

Indivior Statement on the Opiant Pharmaceutical Acquisition

December 23 2022

Statement from Dr. Terry Horton of Indivior on Mainstreaming Addiction Treatment (MAT) Act Passed by Congress